This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Flamel Technologies Achieves Clinical Milestone With Merck Serono On An Extended Release Formulation Of Interferon Beta-1a

Flamel Technologies (Nasdaq: FLML) announced today that it has achieved a clinical development milestone under the terms of its license agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to develop an extended release formulation of interferon beta-1a using the Medusa platform. As a result, Flamel will receive a fee of € 3.0 million. Flamel and Merck Serono entered in a collaboration agreement in December 2007 to develop an extended release formulation of interferon-beta-1a.

Stephen H. Willard, Flamel’s chief executive officer, stated, “We are pleased with the progress that we have been able to achieve in this important development program, and believe that our Medusa platform could offer patients the same active principle as in Merck Serono’s interferon beta-1a, as an extended release formulation.”

Mr. Willard continued, “The Medusa platform is distinct from controlled release platforms of large and small molecules. Medusa has been shown to enable delivery of therapeutic molecules that retain full bioactivity. The applicability of Medusa to a wide range of therapeutic agents is an important advantage of the Medusa platform.”

The Company also announced that it has received a 14-page response to its April 19, 2010 petition regarding the data to be required of drug product marketing applications that seek to rely on FDA's previous approval of Coreg CR. The Company's petition was granted in part and denied in part. A copy of the response is available on Flamel’s website, www.flamel.com.

The Company believes that the FDA’s response recognizes the importance of maintaining appropriate levels of carvedilol phosphate for the entire 24-hour period of a controlled release product dosing period, with regard to all indications treated with extended-release carvedilol products. The FDA response concludes that the Agency intends to apply the standard AUC and Cmax criteria to the bioequivalence evaluation of any ANDA’s referencing Coreg CR and that it will examine Tmax and the overall pharmacokinetic profile during the review process to determine whether any difference between test and reference products may result in a lack of therapeutic equivalence.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs